Our Platform · Results

FROM COMPLEX EVIDENCE TO REVIEWABLE RESULTS.

HERMS connects 25 specialist applications across discovery, development, manufacturing, regulation, access, safety, supply and capital. Each produces structured, source-linked outputs that your experts can review, challenge and act on.

SOURCES IN REVIEW ILLUSTRATIVE LAYOUT · NOT A CLIENT REPORT

Result Types

Results That Support Decisions

Four result types, each designed around a specific decision your team has to make.

Evidence Findings

A structured synthesis of what the evidence shows, where sources agree and where gaps remain.

Supports: whether the evidence is sufficient to proceed.

Readiness Assessment

A criterion-by-criterion view of how prepared a program, process or submission is.

Supports: whether to advance, remediate or pause.

Scenario Comparison

Options set side by side with stated assumptions, trade-offs and uncertainty.

Supports: which path to pursue.

Action Plan

Prioritized steps with named owners, linked to the findings that triggered them.

Supports: what to do next and who is accountable.

Representative Outputs

What Each Assessment Delivers

Six assessment families, each producing defined deliverables that feed a named decision.

Gene Therapy & Genome-Editing Assessment

Connects target biology, vector or editing design, delivery and safety evidence in one reviewable view.

Deliverables
  • Evidence map across target, construct and delivery
  • Risk and data-gap register
  • Translational readiness summary

Decision: whether and how to advance a program.

Manufacturing Technology-Transfer Readiness

Tests whether process knowledge, IP rights and site capability are ready to transfer.

Deliverables
  • Transfer-package completeness review
  • IP and know-how rights map
  • Receiving-site capability gap list

Decision: whether to proceed with a transfer.

Bioprocess & Manufacturing Quality Assessment

Examines process design, control strategy and quality evidence against stated requirements.

Deliverables
  • Control-strategy review
  • Process-validation evidence checklist
  • Deviation and quality-gap summary

Decision: what to resolve before scale-up or release review.

Regulatory & Market-Access Assessment

Links regulatory obligations with pricing, tender and payer evidence needs, market by market.

Deliverables
  • Source-cited obligation set per market
  • Dossier and evidence gap analysis
  • Access pathway and pricing-option comparison

Decision: submission and market-entry strategy.

Safety & Supply Assessment

Brings safety signals and supply risks into one prioritized view.

Deliverables
  • Safety case and signal review summary
  • Supply and cold-chain risk register
  • Escalation and mitigation plan

Decision: where to intervene first to protect patients and availability.

Investment & Portfolio Assessment

Converts scientific, regulatory, manufacturing and market evidence into comparable capital options.

Deliverables
  • Asset evidence and valuation dossier
  • Portfolio scenario comparison
  • Assumption and uncertainty register

Decision: where to allocate or hold capital.

Demonstrated Work

How a Case Study Will Be Documented

Illustrative Workflow · Not a Customer Case Study

No completed-project case study is published here. The structure below shows how each one will be documented once supported by evidence.

1

Problem

The decision the team faced and why existing evidence was hard to review.

2

Scope

Applications, products, markets and questions covered, and what was excluded.

3

Evidence Reviewed

Source types, volume and provenance, listed so reviewers can check coverage.

4

Output Delivered

The assessment, registers and plan handed to the accountable team.

5

Validation Performed

Who reviewed the output, by what method, and what they changed.

6

Limitations

Open gaps, assumptions and conditions under which conclusions should not be relied on.

Measuring Results

Delivered Outputs Versus Measured Outcomes

An output is what HERMS delivers. An outcome is what an independent measure shows. Each measure below is set against a baseline agreed before work begins.

Evidence Completeness

Required evidence items present, against the checklist agreed at kickoff.

Review Turnaround Time

Elapsed time from evidence submission to reviewer-ready output, against the team's current process.

Issue Resolution

Issues raised, closed and reopened over an agreed period, against the starting position.

Source Traceability

Conclusions linked to a citable source, confirmed by sampled reviewer checks.

Milestone Readiness

Criteria met at each milestone gate, against the agreed plan.

No results are reported until a baseline is agreed and measurement is independently reviewed.

Human Review and Accountability

Every Conclusion Shows Its Working

Each analytical conclusion travels with the information a reviewer needs to accept, amend or reject it.

SourcesMethodsAssumptionsUncertaintyReview StatusResponsible Reviewer

Regulatory, clinical, manufacturing-release and investment decisions remain with appropriately authorized people. HERMS outputs inform those decisions. They are not regulatory approval, validated manufacturing readiness or investment authorization.

DEFINE THE RESULT YOUR TEAM NEEDS.

Start by agreeing the workflow, the deliverable, the evidence requirements and the acceptance criteria. We will show you how HERMS would produce it.

ENGINEERING INTELLIGENCE. REVOLUTIONIZING LIFE SCIENCES.

HERMS is the intelligence platform. Its applications are the decision engines. HERMS expert services support implementation and regulated execution of the HERMS intelligence ecosystem, from regulatory and market access to pharmacovigilance, compliance and quality.

Drug registration timelines by country · SFDA, MOHAP, EDE, EDA, EMA and FDA timelines · GCC central registration